INVO Fertility, Inc.

INVO Fertility, Inc. is a healthcare services company dedicated to the fertility market, providing assisted reproductive technology care to patients. Headquartered in Sarasota, Florida, the company's mission is to make advanced fertility care effective, accessible, and empowering for individuals and couples seeking to build families.

The company's core offering is the INVOcell device, an FDA-cleared intravaginal culture (IVC) system that facilitates fertilization and early embryo development within the woman's body. This proprietary technology is presented as a simpler, more natural, and lower-cost alternative to traditional in vitro fertilization (IVF). INVO Fertility also operates its own network of fertility clinics, known as "INVO Centers," and is actively involved in establishing, acquiring, and operating new fertility clinics.

In April 2025, the company, formerly known as NAYA Biosciences, Inc., was renamed INVO Fertility, Inc., and its Nasdaq ticker symbol changed to IVF. This strategic shift followed the separation of its fertility operations from its oncology and autoimmune disease development segments, with NAYA Therapeutics becoming a privately held entity. Steven M. Shum serves as the Chief Executive Officer, with Andrea Goren as Chief Business Officer and Terah Krigsvold as Chief Financial Officer. The company continues to focus on expanding access to advanced fertility treatment globally by offering affordable and accessible options.